biotechnology

Biotech Jason Mast

STAT Plus: Legend says its CAR-T outperformed conventional therapy for multiple myeloma

The Readout LOUD Adam Feuerstein and Meg Tirrell

Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection

Biotech Jason Mast

STAT Plus: Vir CEO George Scangos to retire, after pandemic success

Biotech Jonathan Wosen

STAT Plus: Bay Area biotech uses AI to unlock RNA structures — and find new therapies in the process

Biotech Allison DeAngelis

STAT Plus: Focused exclusively on life sciences, three top investors set out on their own

Adam's Take Adam Feuerstein

STAT Plus: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy

Biotech Laura Ungar — Associated Press

STAT Plus: Promising gene therapy delivers treatment directly to brain

Exclusive Jason Mast

STAT Plus: Calico looking for new chief scientist after celebrated biologist David Botstein quietly retires

Politics Jonathan Wosen

STAT Plus: Liquid-biopsy firm Grail is spending more than ever lobbying Congress

Biotech Jason Mast

STAT Plus: Pliant claims early success in hard-to-treat progressive lung disease

Biotech Allison DeAngelis

STAT Plus: How one private biotech seized on JPM to emerge from stealth and tell its story

On Target Angus Chen

STAT Plus: Is mesothelin a key to tackling solid tumors? Some biotech companies are betting that it is

Biotech Adam Feuerstein

STAT Plus: FDA rejects Lilly’s bid for accelerated approval for its Alzheimer’s drug

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score

First Opinion Paul J. Hastings

STAT Plus: Biopharma leaders helped save democracy. Now what?

On Target Angus Chen

STAT Plus: In the search for therapies for solid tumors, companies are turning to a novel target: claudin-6

Biotech Matthew Herper

STAT Plus: Moderna says RSV vaccine worked, setting stage for competition with GSK and Pfizer

Biotech Jason Mast

STAT Plus: After four years of big talk, mega startup Sana prepares to deliver some data

Biotech Jonathan Wosen

STAT Plus: Liquid biopsy study suggests a better way to decide which colorectal cancer patients need chemo

Biotech Jonathan Wosen

STAT Plus: Invitae’s new CEO on why the genetic testing firm stopped chasing ‘volume at all costs’

Biotech Matthew Herper

Virtual Event: “JPM Recap, Live!” 2023

Biotech Allison DeAngelis

STAT Plus: Biotech startups are hungry for dollars. Here’s what one pharma executive was looking for at JPM

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: ‘We become millionaires and we retire babe’: Former Takeda worker and boyfriend accused of $2.3 million scam of drug firm

Biotech Jason Mast

STAT Plus: Regeneron’s George Yancopoulos admits some regret, but ‘I don’t apologize’

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

#JPM23 in review, the year ahead, & the merits of Miami

Biotech Jonathan Wosen

STAT Plus: BioNTech CEO lays out vision for how mRNA and AI can power personalized medicine

Politics John Wilkerson

STAT Plus: Medicare paves the way for CAR-T in doctors offices

Biotech Jonathan Wosen

STAT Plus: Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome

Biotech Jason Mast

STAT Plus: Still hoping for looser FDA rules, Regeneron says it will test durable antibody for Covid